203 related articles for article (PubMed ID: 35821188)
1. Ecoevolutionary biology of pancreatic ductal adenocarcinoma.
Raja Arul GL; Toruner MD; Gatenby RA; Carr RM
Pancreatology; 2022 Sep; 22(6):730-740. PubMed ID: 35821188
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
3. Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas.
Gkountakos A; Mafficini A; Lou E; Malleo G; Salvia R; Calicchia M; Silvestris N; Racila E; Amin K; Veronese N; Brunetti O; Antonini P; Ingravallo G; Mattiolo P; Saponaro C; Nappo F; Simbolo M; Bariani E; Lonardi S; Fassan M; Milella M; Lawlor RT; Scarpa A; Luchini C
Hum Pathol; 2022 Oct; 128():124-133. PubMed ID: 35850360
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Simbolo M; Silvestris N; Malleo G; Mafficini A; Maggino L; Cocomazzi A; Veghini L; Mombello A; Pezzini F; Sereni E; Martelli FM; Gkountakos A; Ciaparrone C; Piredda ML; Ingravallo G; Paolino G; Nappo F; Rapposelli IG; Frassinetti L; Saragoni L; Lonardi S; Pea A; Paiella S; Fassan M; Brunetti O; Cingarlini S; Salvia R; Milella M; Corbo V; Lawlor RT; Scarpa A; Luchini C
Mod Pathol; 2023 Sep; 36(9):100251. PubMed ID: 37355152
[TBL] [Abstract][Full Text] [Related]
5. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
6. Cancerization of the Pancreatic Ducts: Demonstration of a Common and Under-recognized Process Using Immunolabeling of Paired Duct Lesions and Invasive Pancreatic Ductal Adenocarcinoma for p53 and Smad4 Expression.
Hutchings D; Waters KM; Weiss MJ; Wolfgang CL; Makary MA; He J; Cameron JL; Wood LD; Hruban RH
Am J Surg Pathol; 2018 Nov; 42(11):1556-1561. PubMed ID: 30212393
[TBL] [Abstract][Full Text] [Related]
7. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.
Zhang X; Mao T; Zhang B; Xu H; Cui J; Jiao F; Chen D; Wang Y; Hu J; Xia Q; Ge W; Li S; Yue M; Ma J; Yao J; Wang Y; Wang Y; Shentu D; Zhang X; Chen S; Bai Y; Wang Y; Zhang X; Liu Q; Sun Y; Fu D; Liu Y; Xiong L; Wang L
EBioMedicine; 2022 Mar; 77():103897. PubMed ID: 35231699
[TBL] [Abstract][Full Text] [Related]
11. Molecular Pathogenesis of Pancreatic Cancer.
Grant TJ; Hua K; Singh A
Prog Mol Biol Transl Sci; 2016; 144():241-275. PubMed ID: 27865459
[TBL] [Abstract][Full Text] [Related]
12. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
[TBL] [Abstract][Full Text] [Related]
15. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
[TBL] [Abstract][Full Text] [Related]
16. Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview.
Sikdar N; Saha G; Dutta A; Ghosh S; Shrikhande SV; Banerjee S
Curr Genomics; 2018 Sep; 19(6):444-463. PubMed ID: 30258276
[TBL] [Abstract][Full Text] [Related]
17. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Zhu L; Wang X
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32024063
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
19. Impact of Driver Mutations on the Evolution of Isolated Metachronous Lung Metastasis of Pancreatic Ductal adenocarcinoma.
Vitellius C; Griveaux O; Morvant B; Pedrono E; Venara A; Ingster O; Baize N; Dincuff E; Rousselet MC; Guardiola P; Caroli-Bosc FX
Mol Diagn Ther; 2020 Aug; 24(4):443-449. PubMed ID: 32524539
[TBL] [Abstract][Full Text] [Related]
20. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study.
Toshima F; Watanabe R; Inoue D; Yoneda N; Yamamoto T; Sasahira N; Sasaki T; Matsuyama M; Minehiro K; Tateishi U; Gabata T
AJR Am J Roentgenol; 2021 Dec; 217(6):1353-1364. PubMed ID: 34161128
[No Abstract] [Full Text] [Related]
[Next] [New Search]